Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.

Raymond K Anton Konstantin E Voronin Sarah W BookPatricia K LathamPatrick K RandallWillam Bailey GlenMichaela Hoffman Joseph P Schacht

Published in: Alcoholism, clinical and experimental research (2020)

These results suggest that individuals with AUD with a more opioid-responsive genotype (OPRM1 G carriers) respond better to naltrexone if they have genotypes indicating normal/less dopamine tone (DAT1 10,10 or COMT val,val), while those with a less responsive opioid-responsive genotype (OPRM1 A homozygotes) respond better to naltrexone if they have genotypes indicating greater dopamine tone (DAT1 9-repeat or COMT met carriers). These results could lead to more personalized AUD treatments.

Keyphrases

alcohol use disorder
chronic pain
pain management
cancer therapy
uric acid
clinical trial
prefrontal cortex
genome wide
metabolic syndrome
drug delivery
randomized controlled trial
tyrosine kinase
dna methylation
transcription factor
genome wide identification
phase iii